Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate

Reedijk, 1987, The mechanism of action of platinum antitumour drugs., Pure Appl Chem, 59, 181, 10.1351/pac198759020181 Roberts, 1984, Cisplatin, 118 Tay, 1988, Effects of cis-diamminedichloroplatinum(II) on rabbit kidney in vivo and on rabbit renal proximal tubule cells in culture, Cancer Res, 48, 2538 Prajda, 1989, Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow, In Vivo, 3, 267 Borch, 1989, Biochemical modulation of cisplatin toxicity, Pharmac Ther, 41, 371, 10.1016/0163-7258(89)90114-9 Goel, 1989, Effect of sodium thiosulphate on the pharmacokinetics and toxicity of cisplatin, J Natl Cancer Inst, 81, 1552, 10.1093/jnci/81.20.1552 Borch, 1979, Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate in a rat model, 76, 6611 Borch, 1980, Effect of diethyldithiocarbamate on tumour response to cis-platinum in a rat model, 77, 5441 Jones, 1986, Inhibition of cis-diamminedichloroplatinum(II)-induced renal toxicity in the rat, Cancer Chemother Pharmacol, 17, 38, 10.1007/BF00299863 Bodenner, 1986, Effect of dithiocarbamate on cis-diamminedichloro-platinum(II)-induced cytotoxicity, DNA cross-linking, and γ-glutamyl transpeptidase inhibition, Cancer Res, 46, 2745 Quazi, 1988, Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin, J Natl Cancer Inst, 80, 1486, 10.1093/jnci/80.18.1486 Yuhas, 1980, Treatment of tumours with the combination of WR-2721 and cis-diamminedichloro-platinum(II) or cyclophosphamide, Br J Cancer, 42, 574, 10.1038/bjc.1980.282 Wasserman, 1981, Differential protection against cytotoxic chemo-therapeutic effects on bone marrow CFUs by WR-2721, Cancer Clin Trials, 4, 3 Glover, 1988, Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy, Pharmac Ther, 39, 3, 10.1016/0163-7258(88)90032-0 Shaw, 1988, WR2721 pharmacokinetics, Pharmac Ther, 39, 195, 10.1016/0163-7258(88)90061-7 Calabro-Jones, 1988, Uptake of WR 2721 derivatives by cells in culture: identification of the transported form of the drug, Cancer Res, 48, 3634 Utley, 1985, Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721, Int J Radiat Oncol Biol Phys, 10, 1525, 10.1016/0360-3016(84)90495-4 Fichtinger-Schepman, 1984, A simple method for the inactivation of monofunctionally DNA-bound cis-diamminedichloroplatinum(II), J Inorg Biochem, 21, 103, 10.1016/0162-0134(84)85043-6 Fichtinger-Schepman, 1985, Adducts of the antitumour drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation, Biochemistry, 24, 707, 10.1021/bi00324a025 Dedon, 1987, Characterization of the reactions of platinum antitumour agents with biologic and nonbiologic sulfur-containing nucleophiles, Biochem Pharmacol, 36, 1955, 10.1016/0006-2952(87)90494-1 Treskes, 1991, The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumour agents cisplatin and carboplatin, Biochem Pharmacol, 42, 2125, 10.1016/0006-2952(91)90347-8 Smoluk, 1986, Equilibrium dialysis studies of the binding of radioprotector compounds to DNA, Radiat Res, 107, 194, 10.2307/3576807 Evans, 1983, An in vivo study of the radioprotective effect of diethyldithiocarbamate (DDC), Int J Radiat Oncol Biol Phys, 9, 1635, 10.1016/0360-3016(83)90416-9 Vaughan, 1989, Conformational changes in chromatin structure induced by the radioprotective aminothiol WR 1065, BR J Cancer, 60, 893, 10.1038/bjc.1989.386